Upload Records Snowball Search Search OpenAlex
About the database ScholarIQanswers from OpenAlex
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
PaperCitations, authors & open-access status
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial is a paper indexed in ScholarIQ from OpenAlex. ScholarIQ records 5,545 citations, 2012 year and green oa status.
5,545
Citations
2012
Year
green
OA Status